2002 Laureate
Current position
Group leader, CNRS Research Director (DREx), co-head of the Institute for Clinical Science, Léon Bérard Center, Director of the DEVweCAN LabEx, Director of the Rabelais Institute for Cancer Interdisciplinary Research, deputy Director at the Cancerology Research Center, Lyon, adjunct Professor at the Buck Institute for Age Research, Novato (USA)
Host institution
Cancerology Research Center, Lyon, France CNRS, France
patrick.mehlen@lyon.unicancer.fr
In adults, cell renewal is precisely controlled, notably by a mechanism involving Dependence Receptors in the control of cell death. In certain cancers, cells escape this process, which gives them a supplementary selective advantage to uncontrollably multiply and form tumors. Patrick Mehlen deciphers those mechanisms to offer novel ways to fight cancer.
• 1989-1993 : Undergraduate studies at the Ecole Normale Supérieure (Lyon, France)
• 1995 : Ph. D., University Claude Bernard, Lyon, France, André-Patrick Arrigo's lab
• 1997-1998 : Visiting scientist, Burnham Institute for Clinical Research, La Jolla, USA, Dale Bredesen's Lab
• 1998 : Appointed Group leader at the CGMC, Lyon, France
• Duquesne Price, 2016
• Elected Member of the French Academy of Sciences, 2013
• Advanced Grant from the European Research Council (ERC), 2012
• Fondation Bettencourt Schueller Prize for Life Sciences, 2011
• Laureat of the Pius XI Gold Medal from the Pontifical Academy of Sciences, 2010
• SIlver Medal of the CNRS, 2005
Starting of a clinical trial inspired by Patrick Mehlen’s group results
2017
Non-canonical NOTCH3 signalling limits tumour angiogenesis.
Jul 2017, Nat Commun.
Netrin-1 controls colorectal tumorigenesis by regulating apoptosis
Sep 2004, Nature